Treatment of intestinal graft-versus-host disease using betamethasone enemas.
Intestinal graft-versus-host disease (GVHD) can readily easily induce generalized metabolic disturbance that influences morbidity and mortality after allogeneic bone marrow transplantation. Although adding a new drug or increasing the doses of immunosuppressive agents will probably be effective for controlling intestinal GVHD, the systemic side effects of such therapy cannot be ignored. In this study, we used betamethasone retention enemas as a local treatment for eight patients with refractory and/or severe intestinal GVHD. Six of the eight patients showed improvement of diarrhea and/or abdominal pain, with a reduction in the stage of GVHD. When treatment with betamethasone enemas was continued for 10 to 27 days in the 6 responding patients, no severe toxicity was observed. One patient failed to respond to treatment and another could not tolerate the enemas. Despite some uncertainty regarding the indications and duration of treatment, betamethasone enemas seem to be a potential alternative method for the management of intestinal GVHD.
Wada
H
H
Second Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya City, Hyogo 663-8501, Japan.
Mori
A
A
Okada
M
M
Takatsuka
H
H
Tamura
A
A
Seto
Y
Y
Iwata
N
N
Fujimori
Y
Y
Okamoto
T
T
Takemoto
Y
Y
Kakishita
E
E
D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001623:Betamethasone / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D018791:CD4 Lymphocyte Count; D004733:Enema; D005260:Female; D005938:Glucocorticoids; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007410:Intestinal Diseases / Q000188:drug therapy*; D008297:Male; D014184:Transplantation, Homologous
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D001623:Betamethasone